News Summary

• Soaring use of the medications has pushed up costs ‌for employers.
• Some plan to tell employees they will no longer pay for them in 2027, experts say.
• Instead, employees are expected to purchase direct-to-consumer products.
• Hims had become one of the largest u.s. telehealth providers of weight-loss drugs.
• of Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo.
• The company missed earnings and revenue targets last quarter as it adjusted to new compounding rules with the branded drugs no longer in shortage.